Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart

Kiniksa Pharmaceuticals International, plc

2024-FY EPS reported -$0.60 revenue$423,239,000

ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).
2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.
Terminated MedImmune license for mavrilimumab; effective May 22, 2025.
Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.
Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.